ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1645 • 2012 ACR/ARHP Annual Meeting

    Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases

    Dilrukshie Cooray1, Saleem A. Waraich2, Andrew Phan1, Rosalinda C. Moran1 and George A. Karpouzas1, 1Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Placentia, CA

    Background/Purpose: Patients with rheumatic diseases (RD) are typically treated with conventional and /or biologic disease modifying anti-rheumatic drugs (DMARD's) including tumor necrosis factor inhibitors (TNFi). …
  • Abstract Number: 1646 • 2012 ACR/ARHP Annual Meeting

    The Mechanism of Umbilical Cord Mesenchymal Stem Cells in the Upregulation of Regulatory T Cells by TGF-β1 in Systemic Lupus Erythematosus

    Lingyun Sun1, Dandan Wang2, Lin Lu2 and Xia Li2, 1the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose: Umbilical cord (UC) derived mesenchymal stem cells (MSCs) have shown immunoregulation on various immune cells. The aim of this study is to investigate the…
  • Abstract Number: 1647 • 2012 ACR/ARHP Annual Meeting

    Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids

    Peter M. Izmirly1, Sara Sahl1, Amit Saxena2, Nathalie Costedoat-Chalumeau3, Jean-Charles Piette4, Munther A. Khamashta5, Cecilia Pisoni6, Deborah Friedman7 and Jill P. Buyon1, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Rheumatology, New York University School of Medicine, New York, NY, 3Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 4Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, 5Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 6Section of Rheumatology and Immunology, Centro de Educación, CEMIC, CABA, Argentina, 7Division of Pediatric Cardiology, New York Medical College, Valhalla, NY

    Background/Purpose: Life-threatening cardiac manifestations of neonatal lupus (cardiac-NL) include complete block, endocardial fibroelastosis (EFE) and dilated cardiomyopathy (DCM), all supportive of intense fibrosis at the…
  • Abstract Number: 1648 • 2012 ACR/ARHP Annual Meeting

    Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss

    Michelle Petri1, Anil Mankee2, Ehtisham Akhter2, Hong Fang1 and Laurence S. Magder3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD

    Background/Purpose: Multiple factors, including proteinuria, antiphospholipid syndrome, thrombocytopenia and hypertension, are predictive of pregnancy loss in SLE. In the PROMISSE study of mediators of pregnancy…
  • Abstract Number: 1649 • 2012 ACR/ARHP Annual Meeting

    French Cohort Study of 141 Cases of Autoimmune Congenital Heart Block

    Kateri Levesque1, Alice Maltret2, Mohamed Hamidou3, Moez Jallouli4, Jean Loup Pennaforte5, Pauline Orquevaux5, Jean-Charles Piette6, Zahir Amoura4, Francois Barriere7, Jérome Le Bidois2, Laurent Fermont2, Laurence Cohen8, Olivier Meyer9, Olivier Fain10, Arnaud Theulin11, Hugues Lucron12, Francois Sassolas13, Holly Bezanahary14, Gaëlle Guettrot-Imbert15, Pascal Seve16, Elizabeth Diot17, Nathalie Morel1, Christophe Deligny18, Elisabeth Villain2 and Nathalie Costedoat-Chalumeau19, 1Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, 2Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, 3Internal Medicine Department, Nantes University Hospital, Nantes, France, 4Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 5Hu Robert Debre, CHU Reims, Reims, France, 6Hospital Pitie, Paris, 7Pediatry, CHU Nantes, Nantes, France, 8Cardiology, Institut Jacques Cartier, 9Rheumatology, Hopital Bichat, Paris, France, 10Internal Medicine, Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, Bondy, France, 11Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Cardiology, CHU Fort-de-France, Fort de France, Martinique, 13Cardiology, CHU Lyon, Lyon, France, 14Internal Medicine, University Hospital of Limoges, Limoges, France, 15Internal Medicine, Hopital Gabriel Montpied, Clermont-Ferrand, France, 16Internal medicine, CHU Lyon, Lyon, France, 17Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 18Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 19Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France

    Background/Purpose: Cardiac neonatal lupus manifestations mainly include congenital heart block (CHB), endocardial fibroelastosis and dilated cardiomyopathy.  We report the preliminary results of the French registry…
  • Abstract Number: 1650 • 2012 ACR/ARHP Annual Meeting

    Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy

    Jill P. Buyon1, Aanam Aslam2, Marta M. Guerra2, Michael D. Lockshin3, Carl A. Laskin4, Ware Branch5, Lisa R. Sammaritano6, Michelle Petri7, Joan T. Merrill8, Allen D. Sawitzke9 and Jane E. Salmon6, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 4University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, 5Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT

    Background/Purpose: Renal disease is a critical concern of physicians counseling lupus patients regarding pregnancy. In patients without a history of kidney disease, does pregnancy increase…
  • Abstract Number: 1651 • 2012 ACR/ARHP Annual Meeting

    Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort

    Ben Parker1, Murray B. Urowitz2, Dafna D. Gladman3, Mark Lunt4, Ian N. Bruce5 and Systemic Lupus International Collaborating Clinic (SLICC)6, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 5Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, 6Toronto

    Background/Purpose: The Metabolic Syndrome (MetS) is a clustering of metabolic abnormalities associated with an increased risk of developing diabetes and atherosclerosis, and may add to…
  • Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting

    Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

    Loic Guillevin1, Christian Pagnoux2, Alexandre Karras3, Chahera Khoutra4, Olivier Aumaitre5, Pascal Cohen6, Francois Maurier7, Olivier Decaux8, Hélène Desmurs-Clavel9, Pierre Gobert10, Thomas Quemeneur11, Claire Blanchard-Delaunay12, Pascal Godmer13, Xavier Puechal14, Pierre-Louis Carron15, Pierre yves Hatron16, Nicolas Limal17, Mohamed Hamidou18, Maize Ducret19, Florence Vende20, Elisa Pasqualoni21, Bernard Bonnotte22, Philippe Ravaud23, Luc Mouthon24 and French Vasculitis Study Group (FVSG)25, 1Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 2Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, 3Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4Pneumology, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, 5Department of Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 7HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 8Department of Internal Medicine, Rennes University Hospital, Rennes, France, 9Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, 10Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 11Internal medicine, CHR de Valenciennes, Valenciennes, France, 12Internal Medicine, Centre Hospitalier, Niort, France, 13Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 14Internal Medicine, Hôpital Cochin, Paris, France, 15Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, 16Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 17Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, 18Internal Medicine Department, Nantes University Hospital, Nantes, France, 19Department of Internal Medicine, Centre Hospitalier d'Annecy, Annecy, France, 20Nephrology, Hôpital Bicbat, APHP, Paris, France, 21Department of Internal Medicine, Hôpital Bicbat, APHP, Paris, France, 22Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, 23Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 24Internal Medicine, Hopital Cochin, Paris, France, 25Internal Medicine, Hôpital Cochin, Université Paris–Descartes, Paris, France

    Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…
  • Abstract Number: 1653 • 2012 ACR/ARHP Annual Meeting

    Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term Maintenance Therapy

    Jason Springer1, Benjamin Nutter2, Carol A. Langford3, Gary S. Hoffman4 and Alexandra Villa-Forte5, 1Dept of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 3Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 4Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 5Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Disease remission can be successfully achieved in the majority of patients (pts) with Granulomatosis with polyangiitis (Wegener’s) (GPA).  After remission (rem) is achieved continued…
  • Abstract Number: 1654 • 2012 ACR/ARHP Annual Meeting

    Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial

    Eli Miloslavsky1, Ulrich Specks2, John H. Stone3 and RAVE/ITN Research Group4, 1Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, 2Mayo Clinic, Rochester, MN, 3Rheumatology, Massachusetts General Hospital, Boston, MA, 4Bethesda, MD

    Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…
  • Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting

    An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)

    Carol A. Langford1, David Cuthbertson2, Gary S. Hoffman3, Jeffrey Krischer4, Carol McAlear5, Paul A. Monach6, Philip Seo7, Ulrich Specks8, Steven R. Ytterberg9, Peter A. Merkel5 and for the Vasculitis Clinical Research Consortium5, 1Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 2Department of Biostatistics, University of South Florida, Tampa, FL, 3Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 4University of South Florida, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA, 6Rheumatology, Boston University, Boston, MA, 7Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 8Mayo Clinic, Rochester, MN, 9Rheumatology Division, Mayo Clinic, Rochester, MN

    Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…
  • Abstract Number: 1656 • 2012 ACR/ARHP Annual Meeting

    Treatment of Systemic Necrotizing Vasculitides in Patients ≥65 Years Old: Results of the Multicenter Randomized Cortage Trial

    Christian Pagnoux1, Thomas Quemeneur2, Jacques Ninet3, Elodie Perrodeau4, Elizabeth Diot5, Xavier Kyndt6, Benoit de Wazières7, jean-Luc Reny8, Xavier Puéchal9, Pierre-Yves Leberruyer10, Olivier Lidove11, Philippe Vanhille12, Pascal Godmer13, Aimé Albath-Sadiki14, Boris Bienvenu15, Pascal Cohen16, Luc Mouthon17, Philippe Ravaud4, Loic Guillevin18 and French Vasculitis Study Group (FVSG)19, 1Internal Medicine, Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France, Paris, France, 2Internal medicine, CHR de Valenciennes, Valenciennes, France, 3Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 4Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 5Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 6Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, 7Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, 8Service de médecine interne générale Hôpitaux universitaires de Genève, Geneve, Switzerland, 9National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 10Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France, Reims, France, 11Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 12Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, France, 13Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 14Urc, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du faubourg Saint Jacques, Paris, 75014, France, Paris, France, 15Médecine interne, CHU Côte de Nacre, CAEN, France, 16National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 17Internal Medicine, Hopital Cochin, Paris, France, 18Internal Medicine, Cochin University Hospital, Paris, France, 19Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Université Paris – Descartes, Paris, France

    Background/Purpose: To optimize the therapeutic strategy for the elderly with systemic necrotizing vasculitides (SNV; polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) or…
  • Abstract Number: 1617 • 2012 ACR/ARHP Annual Meeting

    Whole-Body Magnetic Resonance Imaging of Disease Manifestations in Axial and Peripheral Joints and Entheses in Rheumatoid Arthritis Patients

    Mette Bjørndal Axelsen1, Anne Duer2, Iris Eshed3, Jakob M. Møller4, Susanne Juhl Pedersen1 and Mikkel Østergaard5, 1Depart of Rheumatology RM, Glostrup Hospital, Copenhagen, Denmark, 2Department of Radiology, Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, 3Department of Radiology, Sheba Medical Center, Tel Hashomer, Israel, 4Department of Radiology, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 5Copenhagen University Hospital Glostrup, Copenhagen, Denmark

    Background/Purpose: To investigate the ability of whole-body magnetic resonance imaging (WBMRI) to visualize synovitis, bone marrow edema and erosions in patients with rheumatoid arthritis (RA)…
  • Abstract Number: 1618 • 2012 ACR/ARHP Annual Meeting

    Prevalence of Inflammatory Sacroiliitis Assessed On MR Imaging of Inflammatory Bowel Disease: A Retrospective Study Performed On 186 Patients

    Sophie Leclerc-Jacob1, Guillaume Lux2, Anne-Christine Rat1, Valérie Laurent2, Alain Blum2, Isabelle Chary-Valckenaere1, Laurent Peyrin-Biroulet3 and Damien Loeuille1, 1Rheumatology, Nancy Teaching Hospital, Nancy, France, 2Radiology, Nancy Teaching Hospital, Nancy, France, 3Gastroenterology and Hepatology, Nancy Teaching Hospital, Nancy, France

    Background/Purpose: Articular involvements are by far the most common extra-intestinal manifestations in inflammatory bowel disease (IBD). They include peripheral arthritis and inflammatory axial manifestation. Until…
  • Abstract Number: 1619 • 2012 ACR/ARHP Annual Meeting

    Quantification of Bone Marrow Edema by Using Magnetic Resonance Imaging for the Assessment of Neck Pain Only Marginally Reflects Clinical Evaluation in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

    Xenofon Baraliakos1, Frank Heldmann2, Ravi Suppiah3, Fiona M. McQueen4 and Jürgen Braun2, 1Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 4Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand

    Background/Purpose: Despite the differences in the pathogenesis of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), neck pain is a frequent clinical symptom in both diseases…
  • « Previous Page
  • 1
  • …
  • 2492
  • 2493
  • 2494
  • 2495
  • 2496
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology